Literature DB >> 6262783

Early events in herpes simplex virus type 1 infection: photosensitivity of fluorescein isothiocyanate-treated virions.

N DeLuca, D Bzik, S Person, W Snipes.   

Abstract

Herpes simplex virus type 1 is photosensitized by treatment with fluorescein isothiocyante (FITC). The inactivation of FITC-treated virions upon subsequent exposure to light is inhibited by the presence of sodium azide, suggesting the involvement of singlet oxygen in the process. Sodium dodecyl sulfate/polyacrylamide gel electrophoresis revealed that treatment with FITC plus light induces crosslinks in viral envelope glycoproteins. Treatment of virions with high concentrations of FITC (50 micrograms/ml) plus light causes a reduction in the adsorption of the virus to monolayers of human embryonic lung cells. For lower concentrations of FITC (10 micrograms/ml) plus light, treated virions adsorb to the host cells, but remain sensitive to light until entry occurs. The loss of light sensitivity coincides with the development of resistance to antibodies. These results are most consistent with a mechanism of entry for herpes simplex virus involving fusion of the viral membrane with the plasma membrane of the host cell.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6262783      PMCID: PMC319914          DOI: 10.1073/pnas.78.2.912

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  18 in total

1.  Quantitative film detection of 3H and 14C in polyacrylamide gels by fluorography.

Authors:  R A Laskey; A D Mills
Journal:  Eur J Biochem       Date:  1975-08-15

2.  Kinetics of cell fusion induced by a syncytia-producing mutant of herpes simplex virus type I.

Authors:  S Person; R W Knowles; G S Read; S C Warner; V C Bond
Journal:  J Virol       Date:  1975-01       Impact factor: 5.103

3.  Membrane proteins specified by herpes simplex viruses. I. Identification of four glycoprotein precursors and their products in type 1-infected cells.

Authors:  P G Spear
Journal:  J Virol       Date:  1976-03       Impact factor: 5.103

4.  Neutral red with photoinactivation in the treatment of herpes genitalis.

Authors:  A P Roome; A E Tinkler; A L Hilton; D G Montefiore; D Waller
Journal:  Br J Vener Dis       Date:  1975-04

5.  Demonstration of oncogenic potential of mammalian cells transformed by DNA-containing viruses following photodynamic inactivation.

Authors:  J L Li; M A Jerkofsky; F Rapp
Journal:  Int J Cancer       Date:  1975-02-15       Impact factor: 7.396

6.  Transformation of mammalian cells by DNA-containing viruses following photodynamic inactivation.

Authors:  F Rapp; J L Li; M Jerkofsky
Journal:  Virology       Date:  1973-10       Impact factor: 3.616

7.  Relief for Herpes vulvitis.

Authors:  E G Friedrich
Journal:  Obstet Gynecol       Date:  1973-01       Impact factor: 7.661

8.  Eczema herpeticum. Treatment with methylene blue and light.

Authors:  T W Chang; L Weinstein
Journal:  Arch Dermatol       Date:  1975-09

9.  Failure of neutral-red photodynamic inactivation in recurrent herpes simplex virus infections.

Authors:  M G Myers; M N Oxman; J E Clark; K A Arndt
Journal:  N Engl J Med       Date:  1975-11-06       Impact factor: 91.245

10.  Proteins specified by herpes simplex virus. XII. The virion polypeptides of type 1 strains.

Authors:  J W Heine; R W Honess; E Cassai; B Roizman
Journal:  J Virol       Date:  1974-09       Impact factor: 5.103

View more
  10 in total

1.  Relationship of herpes simplex virus genome configuration to productive and persistent infections.

Authors:  Sara A Jackson; Neal A DeLuca
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-09       Impact factor: 11.205

2.  Anti-glycoprotein D antibodies that permit adsorption but block infection by herpes simplex virus 1 prevent virion-cell fusion at the cell surface.

Authors:  A O Fuller; P G Spear
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

3.  Neutralizing monoclonal antibodies specific for herpes simplex virus glycoprotein D inhibit virus penetration.

Authors:  S L Highlander; S L Sutherland; P J Gage; D C Johnson; M Levine; J C Glorioso
Journal:  J Virol       Date:  1987-11       Impact factor: 5.103

4.  Monoclonal antibodies define a domain on herpes simplex virus glycoprotein B involved in virus penetration.

Authors:  S L Highlander; W H Cai; S Person; M Levine; J C Glorioso
Journal:  J Virol       Date:  1988-06       Impact factor: 5.103

5.  Identification of mar mutations in herpes simplex virus type 1 glycoprotein B which alter antigenic structure and function in virus penetration.

Authors:  S L Highlander; D J Dorney; P J Gage; T C Holland; W Cai; S Person; M Levine; J C Glorioso
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

6.  Role of glycoprotein B of herpes simplex virus type 1 in viral entry and cell fusion.

Authors:  W H Cai; B Gu; S Person
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

7.  Early interactions of herpes simplex virus with mouse peritoneal macrophages.

Authors:  B Svennerholm; A Vahlne; E Lycke
Journal:  Infect Immun       Date:  1982-09       Impact factor: 3.441

8.  Syncytium-inducing mutations localize to two discrete regions within the cytoplasmic domain of herpes simplex virus type 1 glycoprotein B.

Authors:  P J Gage; M Levine; J C Glorioso
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

9.  Herpes simplex virus infection can occur without involvement of the fibroblast growth factor receptor.

Authors:  M I Muggeridge; G H Cohen; R J Eisenberg
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

Review 10.  Feasibility of herpes simplex virus type 1 mutants labeled with radionuclides for tumor treatment.

Authors:  Yan-Xia Mi; Ya-Hong Long; Yun-Chun Li
Journal:  World J Gastroenterol       Date:  2008-03-07       Impact factor: 5.742

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.